Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals

(2:57)

Overview of a promising new study of venetoclax in patients with CLL

(3:40)

Why venetoclax is a promising new drug for CLL

(1:34)

Promising results for venetoclax combination therapies in elderly AML

(4:49)

Venetoclax in combination with low-dose cytarabine – a promising regimen for the treatment of AML

(2:38)

Dr. Andreeff Discusses Promise of Venetoclax in AML

(2:6)

Promising results for venetoclax across multiple hematological malignancies

(1:54)

Promising outlooks for venetoclax combinations for MM

(1:22)

Dr. Davies on Promise of Venetoclax in Relapsed/Refractory Myeloma

(1:32)

Long Term Results with Venetoclax for CLL is Very Promising

(2:13)

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

(4:49)

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) a...

(2:29)

The promise of combining venetoclax with gilteritinib for the treatment of FLT3-mutated AML

(1:23)

Preliminary promise for venetoclax and 3+7 in untreated AML

(1:7)

Venetoclax combination studies showing great promise at ASH 2017

(1:43)

Overcoming Resistance to Venetoclax in AML

(42)

Dr. Wang Discusses Promise of Venetoclax in MCL

(1:3)

Venetoclax Resistance: Mechanisms and Treatment Options

(20:43)

Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)

(3:23)

Two Venetoclax Studies Show Promise in CLL Patients - Medpage Today

(6:30)